FINWIRES · TerminalLIVE
FINWIRES

Diagens Biotechnology's 2025 Loss Widens

By

-- Hangzhou Diagens Biotechnology (HKG:2526) booked 67.1 million yuan in attributable loss for 2025, widening from a loss of 43.4 million yuan a year earlier, according to a Hong Kong bourse filing Wednesday.

The medical imaging products maker's shares gained nearly 3% in afternoon trade Thursday.

Loss per share was 0.84 yuan, compared with 0.55 yuan in 2024.

Revenue more than doubled year on year to 164.4 million yuan from 70.4 million yuan.

Related Articles